Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Instituto Valenciano de Infertilidad, Spain |
---|---|
Information provided by: | Instituto Valenciano de Infertilidad, Spain |
ClinicalTrials.gov Identifier: | NCT00505817 |
The primary purpose of this study is to evaluate the effect of the two different protocols (long protocol vs antagonist protocol) on oocyte / embryo quality.
Condition | Intervention | Phase |
---|---|---|
Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality |
Drug: Cetrorelix and Leuprolide |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Crossover Assignment |
The cycles with antagonists of the GnRHa present a series of advantages with respect the GnRHa in an oocyte donation program: treatment cycles are simpler and shorter, a lower amount of dose of gonadotrophins is needed for stimulation, and most important, a decreased rate of ovarian hyperstimulation syndrome is observed. Nevertheless, several clinical trials relate their use to a greater rate of abortion and worse oocyte/ embryo quality. In order to discriminate the endometrial factor from the quality of oocyte cohort, the best strategy is the oocyte donation model. In the present study, for the first time, the effect of different protocols (long versus antagonist protocol) will be studied in the same donor, acting as its own control, undergoing COH. We will compare the COH´s parameters and IVF outcome obtained in the same donor submitted to, firstly, GnRH antagonist protocol (Cetrorelix- n= 45) versus another consecutive cycle with long protocol (Ac. Leuprolide- n= 45).
Ages Eligible for Study: | 18 Years to 34 Years |
Genders Eligible for Study: | Female |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Instituto Valenciano de Infertilidad Spain | |
Valencia, Spain, 46015 |
Principal Investigator: | Marco Melo, MDPhD | Instituto Valenciano de Infertilidad |
Study ID Numbers: | VLC-MM-0706-307-19 |
Study First Received: | July 23, 2007 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00505817 History of Changes |
Health Authority: | Spain: Ministry of Health |
Deslorelin Antineoplastic Agents, Hormonal Leuprolide Hormone Antagonists |
Hormones, Hormone Substitutes, and Hormone Antagonists Cetrorelix Hormones |
Antineoplastic Agents, Hormonal Antineoplastic Agents Leuprolide Fertility Agents, Female Therapeutic Uses Hormone Antagonists |
Fertility Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Cetrorelix Reproductive Control Agents Pharmacologic Actions |